Condition: HIV · HIV Infections · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of HIV suppression in early-treated children.
This description comes directly from the study's public registry record.
Molly Pretorius Holme, MSc · 617-432-4377 · mpretori@hsph.harvard.edu
Always discuss trial participation with your own doctor first.
| Francistown CRS (CRS #31891) | Francistown, Botswana | Recruiting |
| Botswana Harvard Health Partnership CRS (CRS #31833) | Gaborone, Botswana | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508749